News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
AOL.com Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has received an average "Moderate Buy" recommendation from analysts, with an average 12-month price target of $35.57. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.11 EPS against an anticipated $0.06 and $129.86 million in revenue versus $118.85 …
Patrick Burnett, an insider at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 6,700 shares of the company's stock for $174,736 on August 12th, reducing his direct stake by over 5%. This sale follows two earlier transactions in August where he sold an additional 9,255 shares. Despite the …
Patrick Burnett, EVP and CMO of Arcutis Biotherapeutics (NASDAQ:ARQT), sold shares worth $394,896 in two transactions on August 11 and 12, 2026, following the exercise of stock options. The company's shares have seen a 61.64% return over the past year, and recent Q2 2026 …
Arcutis Biotherapeutics (ARQT) insider Patrick Burnett has filed a Form 144 to sell 15,000 shares of common stock through Merrill Lynch on or after August 11, 2026. These shares were acquired via a stock option exercise on January 12, 2024. Burnett previously sold 955 …
Arcutis Biotherapeutics announced the grant of 143,500 restricted stock units (RSUs) and options to purchase 37,000 shares to 24 new employees. These inducement awards were made under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of August 3, 2026. The RSUs …
State Street Corporation has disclosed a 4.7% beneficial ownership stake in Arcutis Biotherapeutics, Inc., amounting to 5,822,840 shares. The filing, a SCHEDULE 13G, indicates that State Street and its investment adviser affiliates collectively manage these shares with shared voting power over 5,507,182 shares and …
Arcutis Biotherapeutics (Nasdaq: ARQT) has granted 143,500 restricted stock units (RSUs) and options to purchase 37,000 shares to 24 new hires. These inducement grants, effective August 3, 2026, vest over four years, subject to continued employment, and were made in accordance with Nasdaq Listing …
(RTTNews) - Arcutis Biotherapeutics, Inc. (ARQT) reported a profit for the second quarter ended June 30, 2026, on higher revenue, primarily attributable to higher demand for ZORYVE products. The pharmaceutical company also highlighted various clinical and business updates and raised its full-year guidance. Company …
Arcutis Biotherapeutics, Inc. reported strong results for the 2026 quarter, with revenue reaching $129.86M and diluted EPS at $0.11, significantly exceeding the prior year's performance. The growth was primarily driven by increased product demand, successful label expansions, and a strategic shift to an internal …
Arcutis Biotherapeutics, Inc. (ARQT) has seen its average 12-month price target raised from $34.62 to $36.62 by 8 analysts, suggesting a 35% potential upside from its August 5 closing price. The consensus rating for ARQT remains "Buy," with 7 Buys and 1 Hold among …
Arcutis Biotherapeutics (ARQT) recently announced its chief commercial officer's resignation, yet reported strong second-quarter 2026 revenue of US$129.86 million and net income of US$15.01 million, alongside raising its full-year 2026 net product sales guidance to US$525 million–US$540 million. The company is also bringing in …
Patrick Burnett, EVP and Chief Medical Officer at Arcutis Biotherapeutics (NASDAQ: ARQT), sold 955 shares of company stock for $24,941 to cover tax withholding obligations. The sale occurred on August 3, 2026, at an average price of $26.1168 per share. Despite this sale, ARQT …
This article reports on the filing of Form 4 for Arcutis Biotherapeutics Inc. on August 6, 2026. Form 4 filings disclose changes in beneficial ownership of company securities by insiders. The brief news item indicates that this information was published by Investing.com.
Arcutis President and CEO Todd Watanabe sold 4,375 shares for $114,275 on August 3, 2026. This transaction was non-discretionary, executed to cover tax obligations from vested restricted stock units, and does not reflect a change in his outlook for the company. Arcutis Biotherapeutics reported …
Arcutis Biotherapeutics reported strong Q2 2026 results, surpassing revenue expectations and achieving profitability due to robust demand for its dermatology product, ZORYVE. The company raised its full-year 2026 revenue guidance to $525 million-$540 million, driven by continued prescription growth, recent FDA approvals for ZORYVE …
This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Arcutis Biotherapeutics Inc (NASDAQ:ARQT) reported strong Q2 2026 net product revenues of $129.9 million, a …
Earnings Call Insights: Arcutis Biotherapeutics (ARQT) Q2 2026 MANAGEMENT VIEW * "I'm happy to report that once again, we made substantial progress across all 3 pillars during the second quarter" (President, CEO & Director Todd Watanabe), describing the company’s "grow, expand, build" strategy for …
Arcutis Biotherapeutics (ARQT) reported Q2 earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.09, and revenues of $129.86 million, surpassing estimates by 6.57%. Despite the strong quarterly performance, the stock has underperformed the S&P 500 year-to-date. The company currently holds a …
Arcutis Biotherapeutics, Inc. Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand growth Company raising 2026 full-year net product sales guidance to $525 …
Arcutis Biotherapeutics, Inc. (ARQT) reported Q2 revenue of $129.9 million, surpassing the FactSet estimate of $118.9 million. The company is a commercial-stage medical dermatology company with a product portfolio including ZORYVE Roflumilast Cream and Foam. Arcutis Biotherapeutics also announced executive changes and raised its …
The article focuses on the "Price to book forward" financial metric for Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT). It appears to be a financial data point or analysis page from TradingView, indicating the company's financial overview without providing specific numerical data in the provided text. …
Arcutis Biotherapeutics focused on pediatric dermatology, a market largely abandoned by larger companies, by prioritizing clinical insights and engaging collaboratively with the FDA. Their drug, ZORYVE (roflumilast), has undergone a disciplined age-extension program, targeting various age groups down to infants as young as three …
Masaru Matsuda, an insider at Arcutis Biotherapeutics (ARQT), has filed a Form 144 to sell 1,230 shares of common stock. The sale is planned for August 3, 2026, through Merrill Lynch on NASDAQ, following the vesting of restricted stock on August 1, 2026. This …
Arcutis Biotherapeutics insider Todd F. Watanabe has filed a Rule 144 notice to sell 4,375 common shares that became eligible for sale through restricted stock vesting on August 1, 2026. This planned disposition follows a previous sale of 3,172 common shares on May 4, …
Search by ticker symbol or company name and select a result to open its chart.